ACCESS
EU-JAMRAI2 aims to provide substantial assistance to Member States (MS) in the development and periodic updating of their National Action Plans (NAPs) on Antimicrobial Resistance (AMR). By offering direct and significant support, the initiative seeks to enhance the capacity of MS to effectively tackle AMR within their healthcare systems. Secondly, EU-JAMRAI2 endeavors to bolster the responsiveness and coordination of health systems across the Union, thereby safeguarding individuals from the threat of AMR. Through improved collaboration and streamlined efforts, the initiative aims to fortify the resilience of healthcare systems against the proliferation of drug-resistant infections.
One of the main objectives of EU-JAMRAI2 in this field is to improve access to selected AMR-related products both for human and veterinarian use:
Focus products
The participating countries in EU-JAMRAI 2 that are working on strengthening access have identified clinically important antibiotics and veterinary vaccines with a vulnerable supply. The products reflect the national context in terms of clinical needs, availability and resistance situation. Products may change during the project.
Please click on a turquoise country to see the national focus products.
France
Amoxicillin, clavulanic acid (human)
Aztreonam (human)
Benzathine benzylpenicillin (human)
Cefixime (human)
Fosfomycin (human)
Phenoxymethylpenicillin (human)
Rifampicin (human)
Rifampicin, isoniazid (human)
Rifampicin, isoniazid, pyrazinamide (human)
Rifapentine (human)
Sulfamethoxazole, trimethoprim (human)
Vaccine for turkey rhinotracheitis virus (Veterinary)
Vaccine for clostridium related diseases in ruminant (Veterinary)
Spain
Amikacin (human)
Aztreonam (human)
Benzathine phenoxymethylpenicillin (human)
Cefadroxil (human)
Trimetoprim and Sulfamethoxazole (human)
Oxytetracycline (veterinary)
Vaccines for hemorrahagic enteritis in turkeys (veterinary)
Vaccines for respiratory disease complex in cattle/sheep/goats (veterinary)
Vaccines for coccidiosis (veterinary)
Belgium
Cefadroxil OR Cefalexin (human)
Daptomycin (human)
Phenoxymethylpenicillin (human)
Procaine-benzylpenicillin OR Benzathine Benzylpenicillin (human)
Rifampicin (human)
Sulfadiazine (human)
Sulfamethoxazole + trimethoprim (human)
Thiamphenicol (human)
Amoxicillin (veterinary)
Cefalexin (veterinary)
Bulgaria
Amphotericin B “liposomal” (human)
Benzylpenicillin (human)
Ceftaroline (human pediatric only)
Daptomycin (human)
Eravacycline (human)
Erythromycin (human)
Fosfomycin (human)
Nitrofurantoin (human)
Phenoxymethylpenicillin (human)
Tobramycin (human)
Denmark
Flucloxacillin (human, pediatric)
Fosfomycin (human)
Nitrofurantoin (human)
Pivmecillinam (human)
Ampicillin (human and veterinay)
Benzylpenicillin (/procaine benzylpenicillin) (human and veterinary)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Rifampicin (human and veterinary)
Amoxicillin (veterinary)
Fucidic acid (veterinary)
Sulfadiazine, Trimethoprim (veterinary)
Finland
Amoxicillin (Human)
Benzylpenicillin sodium (Human)
Nitrofurantoin (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Cloxacillin (veterinary)
ERM vaccine for fish (veterinary)
Gentamicin (veterinary)
Phenoxymethylpenicillin (veterinary)
Procaine benzylpenicillin (veterinary)
Trimethoprim, Sulfonamide (veterinary)
Iceland
Amoxicillin (human and veterinary)
Amoxicillin and beta-lactamase inhibitor (human and veterinary)
Benzylpenicillin / Procaine benzylpenicillin (human and veterinary)
Cefalexin (human and veterinary)
Dicloxacillin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Sulfamethoxazole and trimethoprim / Sulfadiazine and trimethoprim (human and veterinary)
Clindamycin (veterinary)
Enrofloxacinum (veterinary)
Oxytetracycline ( veterinary)
Italy
Amikacin (human)
Azithromycin (human)
Benzathine benzylpenicillin (human)
Chloramphenicol (human)
Clarithromycin (human)
Piperacillin, tazobactam (human)
Netherlands
Amoxicillin (Human)
Amoxicillin, clavuanic acid (Human)
Benzathine benzylpenicillin (Human)
Benzylpenicillin (Human)
Cefazolin (Human)
Ceftazidim (Human)
Ciprofloxacin (Human)
Clindamycin (Human)
Cotrimoxazol (Human)
Doxycycline (Human)
Metronidazole (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Innovative vaccines against emerging and novel animal diseases (veterinary)
Norway
Benzylpenicillin (human)
Dicloxacillin (human)
Doxycycline (human)
Erythromycin or clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human)
Phenoxymethylpenicillin (human)
Pivmecillinam (human)
Spectinomycin. (Human)
TB antibiotics from WHO guidelines (human)
Procaine benzylpenicillin (veterinary)
Salmon vaccines (veterinary)
Poland
Content is not available
Slovenia
Amoxicillin (human)
Cefuroxime (human)
Clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human)
Tuberculosis antibiotics (human)
Vaccination for dengue (human)
Vaccine for erysipelothrix (Veterinary)
Sweden
Amoxicillin (human)
Ceftibuten (human)
Cefixime (human)
Colistin (human)
Phenoxymethylpenicillin (human)
Procaine benzylpenicillin (veterinary)
Rifampicin (human)
Temocillin (human)
Trimethoprim, sulfamethoxazole (human)
Trimethoprim, sulfadiazine (veterinary)
Malta
Amoxicillin (human)
Aztreonam (human)
Cefalexin (human)
Cefazolin (human)
Clindamycin (human)
Co-trimoxazole (human)
Fosfomycin (human)
Temocillin (human)
Oxytetracycline (Veterinary)
Vaccine for bovine parainfluenza virus, bovine respiratory syncytial virus and pasteurella (Veterinary)
Vaccine for bovine rotavirus, bovine coronavirus and escherichia (Veterinary)
Barriers to access
For the focus products participants will identify and analyse the specific barriers to access, within their national contexts, in collaboration with national and European stakeholders.
Targeted interventions
Targeted at the barriers to access, participating countries aim to identify, develop and support the implementation national, regional, and European interventions to strengthen access to the specific focus products.
New Products
When it comes to strengthening access to new technologies, like novel antibiotics and bacteriophages, EU-JAMRAI 2 are aiming to assist DG HERA and other European bodies in their efforts and serve as a discussion forum for these questions.
Webinars AND PRESENTATIONS
Individual dispensing of antibiotics in the Netherlands
September 16, 2024
How do companies forecast anticipated demand?
October 11, 2024
Evidence for use of narrow(er) spectrum antibiotics in primary care
June 19, 2024